# Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

Source: https://onco.cc/key-papers/paper-yamamoto-nature/  
OnCo record `paper-yamamoto-nature` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one pathway page, indexed on Europe PMC as PubMed record 32376951 and published in Nature; the citing page links this DOI, which is how the record was matched.

## Summary

Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion include impaired antigen presentation caused by mutations or loss of heterozygosity of the major histocompatibility complex class I (MHC-I), which has been implicated in resistance to immune checkpoint blockade (ICB) therapy 1-3. However, in pancreatic ductal adenocarcinoma (PDAC), which is resistant to most therapies including ICB 4, mutations that cause loss of MHC-I are rarely found 5 despite the frequent downregulation of MHC-I expression 6-8. Here we show that, in PDAC, MHC-I molecules are selectively targeted for lysosomal degradation by an autophagy-dependent mechanism that involves the autophagy cargo receptor NBR1. PDAC cells display reduced expression of MHC-I at the cell surface and instead demonstrate predominant localization within autophagosomes and lysosomes. Notably, inhibition of autophagy restores surface levels of MHC-I and leads to improved antigen presentation, enhanced anti-tumour T cell responses and reduced tumour growth in syngeneic host mice. Accordingly, the anti-tumour effects of autophagy inhibition are reversed by depleting CD8 + T cells or reducing surface expression of MHC-I. Inhibition of autophagy, either genetically or pharmacologically with chloroquine, synergizes with dual ICB therapy (anti-PD1 and anti-CTLA4 antibodies), and leads to an enhanced anti-tumour immune response. Our findings demonstrate a role for enhanced autophagy or lysosome function in immune evasion by selective targeting of MHC-I molecules for degradation, and provide a rationale for the combination of autophagy inhibition and dual ICB therapy as a therapeutic strategy against PDAC.

Indexed on Europe PMC as PubMed record 32376951 (DOI 10.1038/s41586-020-2229-5). Matched by DOI alone: one pathway page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature
- Year: 2020
- DOI: 10.1038/s41586-020-2229-5
- Authors: Yamamoto K, Venida A, Yano J, et al.
- What it means: One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Nature 2020: https://doi.org/10.1038/s41586-020-2229-5
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32376951/
- Europe PMC: https://europepmc.org/article/MED/32376951

## Connected records

- pathways: [Autophagy](https://onco.cc/pathways/autophagy/)
- journals: [Nature](https://onco.cc/journals/nature/)

---
JSON: https://onco.cc/api/v1/entities/paper-yamamoto-nature.json